Screening the Efficacy of Some Traditional Herbal Drugs for Treatment of Hymenolepis diminuta Infection in Rats

Background: Hymenolepis nana (human infecting tapeworm) and H. diminuta (rodent infecting tapeworm) are currently incriminated to be the cause of non-specific bowel disturbances. They are in most instances resistant to the available anticestodal compounds due to misuse of drugs and probably adaptation of the parasites to the commercially available drugsObjective: Our objective is to study the toxicity and curative efficacy of different medicinal plants that are candidate for the treatment of tapeworm infections in man.Methods: Four medicinal plants were tested for their ability to treat Hymenolepis diminuta tapeworm infection in rats. These plants are Amaranthus viridis, Cucurbita maxima, Hagenia abyssinica and Balanites aegyptiaca. Selection of these plants was based on ethnobotanicalinformation. The evaluation of the efficiency of these medicinal plants was based on the “controlled test design”, modified from Moskey and Harwood10: Following pre-infection screening, and life cycle establishment rats were grouped to six experimental groups for each plant. Stool specimens were collected from all groups, the mean of eggs counts per gram of faeces were counted. The reduction percentage of eggs per gram (EPG) was calculated and time to clear eggs was compared with that of Niclosamide. Niclosamide drug was used in this study as a control treatment14.Results: There were no signs of toxic effect on the rats due to administration of any of the tested medicinal plants. Amaranthus viridis leavs exhibited a very weak efficacy. It did not reduce eggs ineither water or food significantly as compared to the untreated control group (p> 0.05). The deparasitization activity of this plant (35%) was not significant. Similarly, Balanites aegyptiaca seeds were not effective in treatment of the infection in rats. Egg counts and deparasitization infood and water, were not significantly (p> 0.05) different from those of the untreated control group. On the other hand, Cucurbita maxima and Hagenia abyssinica seeds were very effective in the treatment of Hymenolepis diminuta infection in rats. Egg reduction (100%) was highly significant (p< 0.01) in food and water as compared to that of the untreated control group of rats (zero%). C. maxima seeds in food deparasitized 80% of the worms, while Hagenia abyssinica deparasitized 100%.Conclusion: Our conclusion was that Hagenia abyssinica was the most active plant of this group in the treatment of Hymenolepis diminuta infection in rats

CHANGES IN SOME BIOPHYSICAL AND BIOCHEMICAL PARAMETERS IN BLOOD AND URINE OF WORKERS CHRONICALLY EXPOSED TO BENZENE

Objective: Benzene may occur naturally as a component of petroleum, or may be manufactured synthetically. It is found in the environment as a contaminant from both human activities and natural processes, posing serious bio-hazards from chronic exposure.Methods: A total of 330 individual were enrolled to study possible health hazards of benzene contamination; 265 males occupationally chronically exposed to low levels of benzene in their daily activity were compared to 65 healthy individuals of the same socio-economic standard. Benzene workers were divided between 45 workers in printing shops, 70 subjects dealing with benzene containing paints (painters), 75 subjects working in professions related to automotive work (autoworkers) and 75 car drivers.Results: benzene itself was not detected in blood or urine of all participants, but the levels of its metabolites; phenol and t,t-muconic acid, were higher in the blood and urine samples in the group of benzene-exposed workers. The results also indicate that individuals in this group are under oxidative stress. However, neither the determined liver function nor the kidney function tests showed significant deviation from controls. However, the results of the biophysical hematological parameters, including the degree of hemolysis, blood viscosity, RBCs aggregation and form factor were significantly deviated from normal.Conclusion: The deviation of the determined biochemical and biophysical parameters from normal may predispose such workers to a variety of health problems. Early correction of the oxidative stress and the hematological parameters and improvement of working conditions are necessary to prevent their progress to more serious health conditions, especially in children and young adolescents working under similar conditions.Running Title : Chronic exposure to benzene in work plac

Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective

The advent of biologic agents has provided a more specific and targeted approach to the treatment of various hematological malignancies and other autoimmune disorders. Such biologic agents have been relatively well tolerated with fewer adverse events reported as compared with many other chemotherapeutic agents. Rituximab is a monoclonal antibody to the B-cell marker CD20 and is a common biologic agent widely used for the treatment of B-cell lymphoma, lymphoproliferative disorders, and inflammatory conditions that are refractory to conventional treatment, including rheumatoid arthritis and some vasculitides. However, through randomized controlled trials and post-marketing surveillance, an increasing number of serious adverse events are being associated with the use of rituximab, often leading to or complicating an intensive care unit admission. The purpose of this review is to focus on the severe complications that are associated with the use of rituximab and that require critical care. Management and prevention strategies for the most common complications along with some examples of its uses within the critical care setting are also discussed. © 2012 BioMed Central Ltd

Molecular Characterization of Glucose-6-Phosphate Dehydrogenase Deficiency in Abu Dhabi District, United Arab Emirates

Purpose: To investigate the frequency of glucose-6-phosphate dehydrogenase (G6PD) variants and their associated enzyme deficiencies among different age groups of individuals in Abu Dhabi, United Arab Emirates (UAE).Methods: A total of 15,995 patients (6302 UAE nationals and 9693 non-UAE nationals) who presented at Mafraq Hospital, Abu Dhabi, UAE between January 2006 and January 2009 were screened for G6PD deficiency using fluorescent spot test. Molecular analysis including polymerase chain reaction– restriction fragment length polymorphism (PCR-RFLP), denaturing high performance liquid chromatography (DHPLC) and DNA sequencing were utilized to identify common mutations in individuals with G6PD deficiency.Results: The prevalence of G6PD deficiency among UAE nationals was 7.4% and non-UAE nationals 3.8%. UAE males showed prevalence of 11.6% while for UAE females it was 3.6%. The prevalence of G6PD deficiency among non-UAE nationals was 5 and 1.7% for males and females, respectively. The Mediterranean mutation, 563C→T, was predominant in non-UAE nationals.Conclusion: G6PD Mediterranean mutation is the most prevalent mutation underlying G6PD deficiency followed by Aures mutations in both UAE nationals and non-UAE nationals. On the other hand, Africa Awas found to be more in non-UAE compared with UAE nationals.Keywords: Glucose-6-Phosphate Dehydrogenase deficiency, Mutation, Abu Dhabi, Polymerase chain reaction–restriction, Fragment length polymorphis

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.

BackgroundIn the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone receptor-positive (HR(+)) advanced breast cancer. We report on the incidence, time course, severity, and resolution of treatment-emergent adverse events (AEs) as well as incidence of dose modifications during the extended follow-up of this study.Patients and methodsPatients were randomized (2:1) to receive EVE 10 mg/day or placebo (PBO), with open-label EXE 25 mg/day (n = 724). The primary end point was progression-free survival. Secondary end points included overall survival, objective response rate, and safety. Safety evaluations included recording of AEs, laboratory values, dose interruptions/adjustments, and study drug discontinuations.ResultsThe safety population comprised 720 patients (EVE + EXE, 482; PBO + EXE, 238). The median follow-up was 18 months. Class-effect toxicities, including stomatitis, pneumonitis, and hyperglycemia, were generally of mild or moderate severity and occurred relatively early after treatment initiation (except pneumonitis); incidence tapered off thereafter. EVE dose reduction and interruption (360 and 705 events, respectively) required for AE management were independent of patient age. The median duration of dose interruption was 7 days. Discontinuation of both study drugs because of AEs was higher with EVE + EXE (9%) versus PBO + EXE (3%).ConclusionsMost EVE-associated AEs occur soon after initiation of therapy, are typically of mild or moderate severity, and are generally manageable with dose reduction and interruption. Discontinuation due to toxicity was uncommon. Understanding the time course of class-effect AEs will help inform preventive and monitoring strategies as well as patient education.Trial registration numberNCT00863655

Behavioral implications of shortlisting procedures

We consider two-stage “shortlisting procedures” in which the menu of alternatives is first pruned by some process or criterion and then a binary relation is maximized. Given a particular first-stage process, our main result supplies a necessary and sufficient condition for choice data to be consistent with a procedure in the designated class. This result applies to any class of procedures with a certain lattice structure, including the cases of “consideration filters,” “satisficing with salience effects,” and “rational shortlist methods.” The theory avoids background assumptions made for mathematical convenience; in this and other respects following Richter’s classical analysis of preference-maximizing choice in the absence of shortlisting

Crohn's disease activity index and Vienna classification - Is it worthwhile to calculate before surgery?

Background: Crohn's disease (CD) patients with increased disease activity may reveal an increased risk for perioperative complications. The `Crohn's disease activity index' (CDAI) and the `Vienna classification' (VC) were developed for standardized disease activity estimations. The significance of these scores to predict extent, type and early outcome of surgery in CD patients was analyzed. Methods: In 179 surgically treated CD patients, the CDAI and VC were assessed from a prospective database. Relations of the scores with CD risk factors, type, number, location and complications of surgery were analyzed. Results: VC behavior and location subtypes were associated with distinct types of surgery (i.e. `strictureplasty' in `stricturing disease', `colon surgery' in `colon involvement'), but not with surgery type and extent or outcome. Surgery extent (i.e. with 5 vs. 3 `surgical sites' 425 +/- 25 vs. 223.3 +/- 25) and complications (357.1 +/- 36.9 (with) vs. 244.4 +/- 13 (without)) were associated with elevated CDAI levels; however, nicotine abuse remained the only significant risk factor for perioperative complications after multiple logistic regression. Conclusion: The significance of VC or CDAI for predicting the extent of surgery or complications is limited. None of the tested variables except preoperative nicotine abuse influenced the likelihood for perioperative complications. Copyright (c) 2006 S. Karger AG, Base